Allergan and Editas announce $90M CRISPR deal – MedCity News
MedCity News |
Allergan and Editas announce $90M CRISPR deal
MedCity News Of note, Allergan has scooped up licenses pertaining to both CRISPR/Cas9 and CRISPR/Cpf1. The latter was developed through the work of Feng Zhang and collaborators at the Broad Institute, MIT and Harvard — the institutions that Editas licenses its … Allergan and Editas Medicine Enter into Strategic R&D Alliance to … Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing … Editas, Allergan Ink $90M CRISPR-Based Eye Drug Deal |
